NTPCR is a nucleoside-triphosphatase with catalytic activity toward purine and pyrimidine nucleoside triphosphates (ATP, GTP, CTP, TTP, UTP), functioning with lower efficiency on nucleoside diphosphates 1. The protein localizes to cellular membranes and mitochondria, where it exhibits ribonucleoside triphosphate phosphatase activity and possesses RNA-binding capacity, suggesting roles in nucleotide metabolism and RNA regulation. Clinically, NTPCR has emerged as a biomarker in pancreatic pathology. It was identified as one of five discriminatory proteins distinguishing low-grade from high-grade/invasive intraductal papillary mucinous neoplasms (IPMNs) of the pancreas, contributing to a combined five-protein model achieving 94% accuracy in malignancy prediction 1. Additionally, NTPCR was identified among ten purine metabolism-related genes associated with thyroid eye disease (TED), an autoimmune inflammatory disorder, with involvement in purine nucleotide metabolism and RNA splicing pathways 2. Protein-protein interaction network analysis predicts NTPCR interacts with alkaline phosphatase (ALPL) and participates in pathways affecting bone formation, homeostasis, and metabolism, with potential relevance to hypophosphatasia pathogenesis 3. These findings position NTPCR as a pleiotropic enzyme with potential diagnostic value in malignant pancreatic lesions and autoimmune diseases, though mechanistic details require further investigation.